[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353856-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353856-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","endometrial-dysfunction-in-women-with-ovarian-and-uterine-tumors-what-is-known-and-what-should-be-learned","Endometrial Dysfunction in Women with Ovarian and Uterine Tumors - What Is Known and What Should Be Learned","","Multimorbidity is a key global trend across healthcare fields, including gynecology, and is linked with poorer health status. Evidence shows that most women experience at least one gynecological disease, while rising obesity associated with chronic inflammation and hyperestrogenism increases hyperproliferative disorders of the female reproductive system. Benign tumors such as uterine fibroids and benign ovarian tumors may impair ovarian reserve and contribute to infertility and reproduction failures via possible endometrial dysfunction. The article reviews endometrium-related pathophysiology affecting endometrial receptivity and implantation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/endometrial-dysfunction-in-women-with-ovarian-and-uterine-tumors-what-is-known-and-what-should-be-learned/353856/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/endometrial-dysfunction-in-women-with-ovarian-and-uterine-tumors-what-is-known-and-what-should-be-learned/353856.png","ImageObject",300,407,{"name":42,"@type":43},"Margaret","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is endometrial dysfunction considered important in women with ovarian and uterine tumors?","Question",{"text":63,"@type":64},"It may contribute to defective endometrial receptivity, affecting blastocyst adhesion and implantation, which can lead to implantation and reproduction failures.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which benign female reproductive system tumors are highlighted as prevalent?",{"text":68,"@type":64},"Uterine fibroids and benign ovarian tumors, including serous and mucinous cystadenomas, are described as common benign conditions.",{"name":70,"@type":61,"acceptedAnswer":71},"How does multimorbidity relate to gynecological disease trends?",{"text":72,"@type":64},"Multimorbidity is presented as a growing global trend that is associated with worse overall health status and an increasing incidence of proliferative gynecological diseases.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353856,1790533216,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137451207643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Review  \nEndometrial Dysfunction in Women with Ovarian and Uterine Tumors: What Is Known and What Should Be Learned?  \nLiudmila M. Mikhaleva 1, Mekan R. Orazov 2, Evgeny D. Dolgov 1,2, Sergey A. Mikhalev 3,4, Zarina V. Gioeva 1,*, Nikolay K. Shakhpazyan 1, Valentina V. Pechnikova 1,4 and Mikhail Y. Gushchin 1  \nAcademic Editor: Stergios Boussios  \nReceived: 23 January 2026  \nRevised: 24 February 2026  \nAccepted: 24 February 2026  \nPublished: 4 March 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Scientific Research Institute of Human Morphology Named After Academician A.P. Avtsyn of the Federal State Budgetary Scientific Institution “Russian Scientific Center of Surgery Named After Academician B.V.  \nPetrovsky”, 117418 Moscow, Russia; [mikhalevalm@yandex.ru](mikhalevalm@yandex.ru) (L.M.M.); [1586dolgde@gmail.com](1586dolgde@gmail.com) (E.D.D.);  \n[nshakhpazyan@gmail.com](nshakhpazyan@gmail.com) (N.K.S.); [valiagtx@yandex.ru](valiagtx@yandex.ru) (V.V.P.); [guschin.michail@yandex.ru](guschin.michail@yandex.ru) (M.Y.G.)  \n2 Department of Obstetrics and Gynecology, Federal State Autonomous Educational Institution of Higher Education «Peoples’ Friendship University of Russia», 117198 Moscow, Russia; orazov-mr@rudn.ru  \n3 Federal State Autonomous Educational Institution of Higher Education “N.I. Pirogov Russian National Research Medical University” of the Ministry of Health of the Russian Federation, 117997 Moscow, Russia; [mikhalevsa1@zdrav.mos.ru](mikhalevsa1@zdrav.mos.ru)  \n4 Savelyeva Moscow City Clinical Hospital No. 31, 119415 Moscow, Russia  \n* Correspondence: morfolhum@mail.ru or gioeva.zv@med.ru  \nAbstract  \nMultimorbidity is a key global trend across healthcare fields, including gynecology. It is strongly associated with an overall poorer health status. Statistics indicate that in the 21st century most women experience at least one gynecological disease. Meanwhile, thereis a consistent increase in the prevalence of obesity associated with chronic inflammation and hyperestrogenism. Alongside other factors, it leads to a growing prevalence of hyperproliferative diseases of the female reproductive system (FRS), encompassing both benign and malignant conditions. While advanced-stage malignant tumors can be linked to missed detection and wrong checkup strategies, benign neoplasms can compromise the ovarian reserve and thus cause major concerns. The prevailing benign FRS tumors are uterine fibroids (UFs) and benign ovarian tumors (BOTs), including serous and mucinous cystadenomas. It appears that an increase in certain benign FRS tumors is occurring in parallel with a rise in infertility (especially “unexplained infertility”) and reproduction failures, potentially associated with endometrial dysfunction. Thus, the endometrium is currently considered a critical area of research due to its vital role as the site of blastocyst adhesion and implantation, especially in patients with comorbidities. In this context, this article highlights the significance and pathophysiological characteristics of UFs and BOTsand their impact on defective endometrial receptivity.  \nKeywords: endometrial dysfunction; implantation failure; reproductive failure; benign ovarian tumors; serous cystadenoma; mucinous cystadenoma; uterine fibroids  \n1. Benign Ovarian and Uterine Tumors: The Significance, Trends, and Global Burden  \nAt the turn of the 20th and 21st centuries, the advanced technologies, automation, and algorithmization of diagnostic and therapeutic processes have driven a profound evolution in medical science. Nevertheless, the prevalence of multimorbidity is demonstrating continuous growth globally. And this ongoing trend is clearly observed in gynecology. The global situation regarding comorbidities is a growing and progressively severe public  \nhealth challenge worldwide (for i","cbCaiortqEDjOJMu","https://ap.wps.com/l/cbCaiortqEDjOJMu","pdf",720987,14,"English","# Abstract\n# Benign Ovarian and Uterine Tumors: The Significance, Trends, and Global Burden","[{\"question\":\"Why is endometrial dysfunction considered important in women with ovarian and uterine tumors?\",\"answer\":\"It may contribute to defective endometrial receptivity, affecting blastocyst adhesion and implantation, which can lead to implantation and reproduction failures.\"},{\"question\":\"Which benign female reproductive system tumors are highlighted as prevalent?\",\"answer\":\"Uterine fibroids and benign ovarian tumors, including serous and mucinous cystadenomas, are described as common benign conditions.\"},{\"question\":\"How does multimorbidity relate to gynecological disease trends?\",\"answer\":\"Multimorbidity is presented as a growing global trend that is associated with worse overall health status and an increasing incidence of proliferative gynecological diseases.\"}]","Endometrial Dysfunction in Women with Ovarian and Uterine Tumors - What Is Known and What Should Be Learned | PDF",1790107596,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a00b7cf6f0cc2f5e1f4251e920ddef3.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/66a57b2e87f2d6a38b430b8891bb58f0.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e17a67cb8ff7ac73f3ac9b954c20c23.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b568fef367b071b4761193c27ab54607.webp",980,1385]